Volume 28, Number 3—March 2022
Dispatch
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
Table 1
Risk factors | No. (%), n = 1,282 | No. seropositive/ no. tested (%) | OR (95% CI) | Adjusted OR (95% CI)† |
GMC, EU/mL (95% CI) | GMC ratio (95% CI) | Adjusted GMC ratio (95% CI)† |
---|---|---|---|---|---|---|---|
Living in a village or town with Ebola cases, n = 1,281 | |||||||
N | 199 (15.5) | 10/198 (5.1) | Referent, p = 0.049 |
Referent, p = 0.125 |
49 (40–58) | Referent, p = 0.010 |
Referent, p = 0.882 |
Y |
1,082 (84.5) |
97/1,073 (9.0) |
1.9 (1.0–3.6) |
1.7 (0.8–3.3) |
65 (60–71) |
1.3 (1.1–1.6) |
1.0 (0.8–1.3) |
Knowing someone who had Ebola | |||||||
No, don't know | 1,044 (81.4) | 82/1,036 (7.9) | Referent, p = 0.193 |
61, 56–67) | Referent, p = 0.204 |
||
Y |
238 (18.6) |
25/236 (10.6) |
1.4 (0.9–2.2) |
70 (57–85) |
1.1 (0.92–1.4) |
||
No. EVD cases known by participant | |||||||
0 | 1,044 (81.4) | 82/1,036 (7.9) | Referent, p = 0.55 |
61 (56–67) | Referent, p = 0.382 |
||
1 | 125 (9.8) | 13/125 (10.4) | 1.4 (0.7–2.5) | 64 (49–85) | 1.1 (0.8–1.4) | ||
2–3 | 66 (5.2) | 8/65 (12.3) | 1.6 (0.8–3.5) | 84 (57–124) | 1.4 (0.9–2.0) | ||
>3 |
47 (3.7) |
4/46 (8.7) |
1.1 (0.4–3.2) |
66 (44–99) |
1.1 (0.7–1.6) |
||
Closest relationship with an EVD case, n = 1,280 | |||||||
No relationship‡ | 1,044 (81.5) | 82/1,036 (7.9) | Referent, p = 0.197 |
61, 56–67) | Referent, p = 0.259 |
||
Close family§ | 27 (2.1) | 1/27 (3.7) | 0.5 (0.1–3.3) | 52 (33–81) | 0.9 (0.5–1.3) | ||
Other relative | 52 (4.1) | 6/51 (11.8) | 1.6 (0.6–3.7) | 64 (42–96) | 1.0 (0.7–1.6) | ||
Friend | 59 (4.6) | 4/59 (6.8) | 0.8 (0.3–2.4) | 64 (45–91) | 1.1 (0.7–1.5) | ||
Community member |
98 (7.7) |
14/97 (14.4) |
2.0 (1.1–3.7) |
86 (62–120) |
1.4 (1.0–2.0) |
||
Living in the same household with an EVD case, n = 1,280 | |||||||
N | 1,269 (99.1) | 107/1,260 (8.5) | – | 63 (58–68) | Referent, p = 0.814 |
||
Y |
11 (0.9) |
0/10 (0.0) |
– |
56 (31–102) |
0.9 (0.5–1.6) |
||
Caring for an EVD case, n = 1,281 | |||||||
N | 1,272 (99.3) | 107/1,262 (8.5) | – | 63 (58–68) | Referent, p = 0.600 |
||
Y |
9 (0.7) |
0/9 (0.0) |
– |
48 (24–98) |
0.8 (0.4–1.6) |
||
Direct body contact with an EVD case, n = 1,281 | |||||||
N | 1,275 (99.5) | 107/1,265 (8.5) | – | 62 (57–67) | Referent, p = 0.640 |
||
Y |
6 (0.5) |
0/6 (0.0) |
– |
83 (28–242) |
1.3 (0.5–3.9) |
||
Attending a funeral of an EVD case | |||||||
N | 1,263 (98.5) | 105/1,254 (8.4) | Referent, p = 0.691 |
62 (57–67) | Referent, p = 0.346 |
||
Y |
19 (1.5) |
2/18 (11.1) |
1.4 (0.3–6.0) |
87 (37–204) |
1.4 (0.6–3.3) |
||
Healthcare frontline worker during EVD outbreak | |||||||
No, NA¶ | 1,254 (97.8) | 105/1,244 (8.4) | Referent, p = 0.802 |
63 (58–69) | Referent, p = 0.798 |
||
Y | 28 (2.2) | 2/28 (7.1) | 0.8 (0.2–3.6) | 58 (36–93) | 0.9 (0.6–1.5) |
*Seropositivity defined as >607 EU/mL. EBOV GP–specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. EBOV GP, Ebola virus glycoprotein; EU, ELISA units; EVD, Ebola virus disease; GMC, geometric mean concentration; NA, not applicable; OR, odds ratio. †Adjusted for age and sex. ‡Participant did not know anyone with Ebola. §Participant was the parent or child or spouse or sibling of an EVD case. ¶Not applicable because participant was a child or did not have a job.
Page created: February 06, 2022
Page updated: February 22, 2022
Page reviewed: February 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.